The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies
| Autor: | Chan Yong Park, Sun-Hye Yang, Sun-Young Jung, Kwang-Beom Lee |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty endocrine system Uterine cervical neoplasms medicine.drug_class medicine.medical_treatment Gonadotropin-releasing hormone Gonadotropin releasing hormone agonist Ovarian neoplasms Follicle-stimulating hormone Gonadotropin-releasing hormone agonist Internal medicine medicine Fertility preservation Gynecology Chemotherapy Pregnancy business.industry Obstetrics and Gynecology Gynecologic Oncology medicine.disease Premature ovarian failure Adjuvant chemotherapy Original Article business hormones hormone substitutes and hormone antagonists Hormone |
| Zdroj: | Obstetrics & Gynecology Science |
| ISSN: | 2287-8580 2287-8572 |
| Popis: | Objective To assess the effects of a gonadotropin-releasing hormone agonist (GnRH-a) depot (Leuprolide acetate) in women with gynecologic cancer receiving chemotherapy while taking a continuous add-back on the prevention of premature ovarian failure. Methods Fourteen premenopausal patients with gynecological malignancies who had undergone conservation of ovaries surgery received a GnRH-a depot plus add-back until chemotherapy was completed. Four weeks thereafter, a hormonal profile (follicle stimulating hormone) was measured. Results The mean follicle stimulating hormone level was 15.8 IU/L. All patients exhibited a restoration of ovarian failure during follow-up. One patient became pregnant during the follow-up period. Conclusion In the short term, GnRH-a appears to protect ovarian function and ability to achieve pregnancy following chemotherapy. The result of our study needs further elucidation in a large randomized controlled trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|